
According to Benzinga Pro data, during Q4, Castle Biosciences (NASDAQ:CSTL) posted sales of $25.04 million. Earnings were up 45.47%, but Castle Biosciences still reported an overall loss of $6.43 million. Castle Biosciences collected $23.48 million in revenue during Q3, but reported earnings showed a $11.79 million loss.